Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: Pooled results from randomized phase III trials

被引：2
|
作者：
Gordon, K
Pariser, D
Langley, R
Caro, I
机构：
[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
[2] Virginia Clin Res, Norfolk, VA USA
[3] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[4] Dalhousie Univ, Sch Med, Halifax, NS, Canada
[5] Genentech Inc, San Francisco, CA 94080 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2004年 / 50卷 / 03期
关键词：
D O I：
10.1016/j.jaad.2003.10.010
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P4
引用
收藏
页码：P1 / P1
页数：1
相关论文
共 50 条
  • [1] Impact of efalizumab on patient-reported outcomes in patients with moderate to severe plaque psoriasis: Pooled results from three randomized phase III trials
    Menter, A
    Hamilton, T
    Caro, I
    Chen-Rundle, A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156
  • [2] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Gold, Linda Stein
    Merola, Joseph F.
    Peterson, Luke
    Wixted, Krista
    Cross, Nancy
    Deherder, Delphine
    Thaci, Diamant
    JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
  • [3] Bimekizumab in patients with moderate-to-severe plaque psoriasis by bodyweight: pooled results from phase III trials
    Pinter, A.
    Strober, B.
    Rosmarin, D.
    Gisondi, P.
    Vanvoorden, V.
    Peterson, L.
    Madden, C.
    de Cuyper, D.
    Warren, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E48 - E49
  • [4] Efficacy and safety of secukinumab by age group in patients with moderate-to-severe plaque psoriasis: Pooled analysis of 4 phase III trials
    Draelos, Zoe
    Kempers, Steven
    Helfrich, Yolanda
    Meng, Xiangyi
    Fox, Todd
    Nyirady, Judit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB247 - AB247
  • [5] Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis
    Leonardi, C
    Goffe, B
    Sobell, J
    Caro, I
    Wang, X
    Papp, K
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A58 - A58
  • [6] Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Rosmarin, David
    Lebwohl, Mark
    Peterson, Luke
    Madden, Cynthia
    de Cuyper, Dirk
    Davies, Owen
    Thaci, Diamant
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (04) : 477 - 485
  • [7] Safety and efficacy of efalizumab therapy for elderly patients with moderate to severe chronic plaque psoriasis
    Gottlieb, A
    Lizzul, P
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P194 - P194
  • [8] Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials
    McMichael, Amy
    Desai, Seemal R.
    Qureshi, Aamir
    Rastogi, Shipra
    Alexis, Andrew F.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (02) : 267 - 276
  • [9] Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials
    Amy McMichael
    Seemal R. Desai
    Aamir Qureshi
    Shipra Rastogi
    Andrew F. Alexis
    American Journal of Clinical Dermatology, 2019, 20 : 267 - 276
  • [10] Efficacy and safety of efalizumab in patients with chronic moderate to severe plaque psoriasis: Results from a postapproval phase IIIb/IV study (control II)
    Lotti, Torello
    Licu, Daiana
    Chimenti, Sergio
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB179 - AB179
12345